229 related articles for article (PubMed ID: 36906277)
21. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations.
DiGennaro J; Sallman DA
Acta Haematol; 2024; 147(2):175-185. PubMed ID: 38052186
[TBL] [Abstract][Full Text] [Related]
22. Acute Myeloid Leukemia and Myelodysplastic Syndromes with
Sill H; Zebisch A; Haase D
Clin Cancer Res; 2020 Oct; 26(20):5304-5309. PubMed ID: 32816950
[TBL] [Abstract][Full Text] [Related]
23. Transplant for TP53-mutated MDS and AML: because we can or because we should?
Versluis J; Lindsley RC
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):522-527. PubMed ID: 36485102
[TBL] [Abstract][Full Text] [Related]
24. Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML.
Nawas MT; Kosuri S
Blood Adv; 2024 Feb; 8(3):553-561. PubMed ID: 38096805
[TBL] [Abstract][Full Text] [Related]
25. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with
Ciurea SO; Chilkulwar A; Saliba RM; Chen J; Rondon G; Patel KP; Khogeer H; Shah AR; Randolph BV; Perez JMR; Popat U; Hosing CM; Bashir Q; Mehta R; Al-Atrash G; Im J; Khouri IF; Kebriaei P; Champlin RE
Blood; 2018 Jun; 131(26):2989-2992. PubMed ID: 29769261
[No Abstract] [Full Text] [Related]
27. Comparison of Outcomes of Myeloablative Allogeneic Stem Cell Transplantation for Pediatric Patients with Bone Marrow Failure, Myelodysplastic Syndrome and Acute Myeloid Leukemia with and without Germline GATA2 Mutations.
Hofmann I; Avagyan S; Stetson A; Guo D; Al-Sayegh H; London WB; Lehmann L
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1124-1130. PubMed ID: 32088370
[TBL] [Abstract][Full Text] [Related]
28. Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation.
Heuser M; Gabdoulline R; Löffeld P; Dobbernack V; Kreimeyer H; Pankratz M; Flintrop M; Liebich A; Klesse S; Panagiota V; Stadler M; Wichmann M; Shahswar R; Platzbecker U; Thiede C; Schroeder T; Kobbe G; Geffers R; Schlegelberger B; Göhring G; Kreipe HH; Germing U; Ganser A; Kröger N; Koenecke C; Thol F
Ann Hematol; 2017 Aug; 96(8):1361-1372. PubMed ID: 28612220
[TBL] [Abstract][Full Text] [Related]
29. TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.
Shah MV; Tran ENH; Shah S; Chhetri R; Baranwal A; Ladon D; Shultz C; Al-Kali A; Brown AL; Chen D; Scott HS; Greipp P; Thomas D; Alkhateeb HB; Singhal D; Gangat N; Kumar S; Patnaik MM; Hahn CN; Kok CH; Tefferi A; Hiwase DK
Blood Cancer J; 2023 Apr; 13(1):51. PubMed ID: 37041128
[TBL] [Abstract][Full Text] [Related]
30. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
[TBL] [Abstract][Full Text] [Related]
31. Defining incidence, risk factors, and impact on survival of central line-associated blood stream infections following hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Lukenbill J; Rybicki L; Sekeres MA; Zaman MO; Copelan A; Haddad H; Fraser T; DiGiorgio MJ; Hanna R; Duong H; Hill B; Kalaycio M; Sobecks R; Bolwell B; Copelan E
Biol Blood Marrow Transplant; 2013 May; 19(5):720-4. PubMed ID: 23380342
[TBL] [Abstract][Full Text] [Related]
32. Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study.
Versluis J; Saber W; Tsai HK; Gibson CJ; Dillon LW; Mishra A; McGuirk J; Maziarz RT; Westervelt P; Hegde P; Mukherjee D; Martens MJ; Logan B; Horowitz M; Hourigan CS; Nakamura R; Cutler C; Lindsley RC;
J Clin Oncol; 2023 Oct; 41(28):4497-4510. PubMed ID: 37607457
[TBL] [Abstract][Full Text] [Related]
33. Molecular Characterization and Clinical Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Patients With TP53 Mutation.
Li Y; Wan H; Jing Y
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):841-851. PubMed ID: 34376372
[TBL] [Abstract][Full Text] [Related]
34. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes.
Nazha A; Hu ZH; Wang T; Lindsley RC; Abdel-Azim H; Aljurf M; Bacher U; Bashey A; Cahn JY; Cerny J; Copelan E; DeFilipp Z; Diaz MA; Farhadfar N; Gadalla SM; Gale RP; George B; Gergis U; Grunwald MR; Hamilton B; Hashmi S; Hildebrandt GC; Inamoto Y; Kalaycio M; Kamble RT; Kharfan-Dabaja MA; Lazarus HM; Liesveld JL; Litzow MR; Majhail NS; Murthy HS; Nathan S; Nishihori T; Pawarode A; Rizzieri D; Sabloff M; Savani BN; Schachter L; Schouten HC; Seo S; Shah NN; Solh M; Valcárcel D; Vij R; Warlick E; Wirk B; Wood WA; Yared JA; Alyea E; Popat U; Sobecks RM; Scott BL; Nakamura R; Saber W
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2139-2146. PubMed ID: 32781289
[TBL] [Abstract][Full Text] [Related]
35. Up-front allogeneic hematopoietic cell transplantation in acute myeloid leukemia arising from the myelodysplastic syndrome.
Choi Y; Kim SD; Park YH; Lee JS; Kim DY; Lee JH; Lee KH; Seol M; Lee YS; Kang YA; Jeon M; Jung AR; Lee JH
Acta Haematol; 2015; 133(2):183-92. PubMed ID: 25323649
[TBL] [Abstract][Full Text] [Related]
36. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
[No Abstract] [Full Text] [Related]
37. TP53 mutation in allogeneic hematopoietic cell transplantation for de novo myelodysplastic syndrome.
Kim YJ; Jung SH; Hur EH; Choi EJ; Lee KH; Yim SH; Kim HJ; Kwon YR; Jeon YW; Lee SH; Chung YJ; Lee JH
Leuk Res; 2018 Nov; 74():97-104. PubMed ID: 30343213
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.
Kim K; Maiti A; Loghavi S; Pourebrahim R; Kadia TM; Rausch CR; Furudate K; Daver NG; Alvarado Y; Ohanian M; Sasaki K; Short NJ; Takahashi K; Yilmaz M; Tang G; Ravandi F; Kantarjian HM; DiNardo CD; Konopleva MY
Cancer; 2021 Oct; 127(20):3772-3781. PubMed ID: 34255353
[TBL] [Abstract][Full Text] [Related]
39. [Outcomes of 138 myelodysplastic syndrome patients with HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation].
Wang QQ; Liu ZX; Zhao XL; Zhang GX; Yao JF; Zheng XH; Zhang LN; Shen YY; Zhao XL; He Y; Huang Y; Zhang RL; Wei JL; Ma QL; Pang AM; Yang DL; Zhai WH; Jiang EL; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):132-137. PubMed ID: 32135630
[No Abstract] [Full Text] [Related]
40.
Ball S; Loghavi S; Zeidan AM
Leuk Lymphoma; 2023 Mar; 64(3):540-550. PubMed ID: 36323304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
